Abstract | BACKGROUND: In adults with sickle cell disease (SCD), an increased tricuspid regurgitant velocity (TRV) measured by Doppler echocardiography, an increased serum N-terminal pro- brain natriuretic peptide (NT-pro-BNP) level, and pulmonary hypertension (PH) diagnosed by right heart catheterization (RHC) are independent risk factors for mortality. METHODS: A multidisciplinary committee was formed by clinician-investigators experienced in the management of patients with PH and/or SCD. Clinically important questions were posed, related evidence was appraised, and questions were answered with evidence-based recommendations. Target audiences include all clinicians who take care of patients with SCD. RESULTS: Mortality risk stratification guides decision making. An increased risk for mortality is defined as a TRV equal to or greater than 2.5 m/second, an NT-pro-BNP level equal to or greater than 160 pg/ml, or RHC-confirmed PH. For patients identified as having increased mortality risk, we make a strong recommendation for hydroxyurea as first-line therapy and a weak recommendation for chronic transfusions as an alternative therapy. For all patients with SCD with elevated TRV alone or elevated NT-pro-BNP alone, and for patients with SCD with RHC-confirmed PH with elevated pulmonary artery wedge pressure and low pulmonary vascular resistance, we make a strong recommendation against PAH-specific therapy. However, for select patients with SCD with RHC-confirmed PH who have elevated pulmonary vascular resistance and normal pulmonary capillary wedge pressure, we make a weak recommendation for either prostacyclin agonist or endothelin receptor antagonist therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy. CONCLUSIONS: Evidence-based recommendations for the management of patients with SCD with increased mortality risk are provided, but will require frequent reassessment and updating.
|
Authors | Elizabeth S Klings, Roberto F Machado, Robyn J Barst, Claudia R Morris, Kamal K Mubarak, Victor R Gordeuk, Gregory J Kato, Kenneth I Ataga, J Simon Gibbs, Oswaldo Castro, Erika B Rosenzweig, Namita Sood, Lewis Hsu, Kevin C Wilson, Marilyn J Telen, Laura M Decastro, Lakshmanan Krishnamurti, Martin H Steinberg, David B Badesch, Mark T Gladwin, American Thoracic Society Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease |
Journal | American journal of respiratory and critical care medicine
(Am J Respir Crit Care Med)
Vol. 189
Issue 6
Pg. 727-40
(Mar 15 2014)
ISSN: 1535-4970 [Electronic] United States |
PMID | 24628312
(Publication Type: Journal Article, Practice Guideline)
|
Chemical References |
- Anticoagulants
- Antihypertensive Agents
- Antisickling Agents
- Phosphodiesterase 5 Inhibitors
- Hydroxyurea
|
Topics |
- Adult
- Anemia, Sickle Cell
(complications, drug therapy, mortality)
- Anticoagulants
(therapeutic use)
- Antihypertensive Agents
(therapeutic use)
- Antisickling Agents
(therapeutic use)
- Cardiac Catheterization
- Decision Support Techniques
- Echocardiography, Doppler
- Erythrocyte Transfusion
- Humans
- Hydroxyurea
(therapeutic use)
- Hypertension, Pulmonary
(diagnosis, etiology, mortality, therapy)
- Phosphodiesterase 5 Inhibitors
(therapeutic use)
- Risk Assessment
- Severity of Illness Index
|